Wendy Shutler
Payments from drug & device makers
Across 128 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$396
- Pfizer$234
- Novo Nordisk$208
- AstraZeneca$202
- Boehringer Ingelheim$180
- Amarin Pharma, Inc.$85
- plus $709 from 20 others
What the payments were for
- Food & beverage$2,013100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $396 |
| Pfizer | 12 | $234 |
| Novo Nordisk | 14 | $208 |
| AstraZeneca | 13 | $202 |
| Boehringer Ingelheim | 11 | $180 |
| Amarin Pharma, Inc. | 5 | $85 |
| Bayer | 5 | $84 |
| Lilly USA, LLC | 5 | $81 |
| Astellas Pharma US Inc | 2 | $48 |
| Merck | 3 | $42 |
| Exact Sciences | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Dexcom, Inc. | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Abbott | 2 | $38 |
| Novartis | 2 | $37 |
| Amgen | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Zealand Pharma US, Inc. | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| GSK | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$2,013 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $39,735 |
| EliquisApixaban | 26 | $34,028 |
| JardianceEmpagliflozin | 19 | $27,600 |
| TrulicityDulaglutide | 14 | $12,693 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $7,213 |
| Aripiprazole | 22 | $3,231 |
| Atorvastatin Calcium | 257 | $2,748 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,724 |
| SynthroidLevothyroxine Sodium | 56 | $2,059 |
| Metoprolol Succinate | 88 | $1,776 |
| Levothyroxine Sodium | 174 | $1,556 |
| Pioglitazone Hcl | 71 | $1,412 |
| MyrbetriqMirabegron | 12 | $1,402 |
| PaxlovidNirmatrelvir/Ritonavir | 11 | $1,347 |
| Pantoprazole Sodium | 92 | $1,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $208 | $39,73532 claims |
| PfizerEliquis, Paxlovid | $234 | $35,37537 claims |
| Boehringer IngelheimJardiance | $180 | $27,60019 claims |
| Lilly USA, LLCTrulicity | $81 | $12,69314 claims |
| MerckJanumet | $42 | $7,21312 claims |
| AbbVieSynthroid | $396 | $2,05956 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $1,40212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.
Other family in Lima
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.